source
- FDA approves Revolution Medicines' daraxonrasib for second-line pancreatic cancerThe U.S. Food and Drug Administration announced approval of Revolution Medicines' drug daraxonrasib for patients with pancreatic cancer who have already received prior therapy. The approval marks…
- Spyre shares plunge as rheumatoid arthritis trial of SPY072 falls short of internal targetSpyre Therapeutics reported that its antibody SPY072 did not meet the company’s internal criteria in a mid‑stage rheumatoid arthritis trial, despite showing some activity. The placebo‑controlled s…